SEC Form 4 · accession 0000905148-26-003040
RIGEL PHARMACEUTICALS INC · RIGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lisa Rojkjaer
Officer — EVP, Chief Medical Officer
Period of report
Jun 17, 2026
Accepted (ET)
Jun 22, 2026 · 4:11 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001034842
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F2 | $14.90 | Jun 17, 2026 | A | 9,375 | A | — | Mar 27, 2034 | Common Stock | 9,375 | 9,375 | D |
| Employee Stock Option (right to buy)F3,F4 | $22.49 | Jun 17, 2026 | A | 7,394 | A | — | Jan 29, 2035 | Common Stock | 7,394 | 7,394 | D |
Explanation of responses
- F1The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.
- F2The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.
- F3The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.
- F4The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.